Wei Ding

Title: The Innovations of Wei Ding

Introduction

Wei Ding is a notable inventor based in Salt Lake City, Utah. He has made significant contributions to the field of genetics, particularly in relation to coronary heart disease. His work has implications for diagnosing and treating various metabolic disorders.

Latest Patents

Wei Ding holds a patent for the Chromosome 11-linked coronary heart disease susceptibility gene CHD1. This patent focuses on the human coronary heart disease susceptibility gene (CHD1), with some alleles linked to an increased risk of coronary heart disease. The patent also addresses germline mutations in the CHD1 gene and their potential use in diagnosing predisposition to coronary heart disease and metabolic disorders. These disorders include hypoalphalipoproteinemia, familial combined hyperlipidemia, insulin resistant syndrome X, obesity, diabetes, and dyslipidemic hypertension. Furthermore, the patent discusses presymptomatic therapy for individuals carrying deleterious alleles of the CHD1 gene, including gene therapy, protein replacement therapy, and the administration of protein mimetics and inhibitors. It also covers the screening of drugs for dyslipidemic therapy.

Career Highlights

Wei Ding is currently employed at Myriad Genetics, Inc., where he continues to advance research in genetics and its applications in medicine. His work has been instrumental in understanding the genetic factors contributing to coronary heart disease.

Collaborations

Wei Ding has collaborated with notable colleagues, including Dennis G. Ballinger and Susanne Wagner. Their combined expertise has contributed to the advancement of research in genetic susceptibility to diseases.

Conclusion

Wei Ding's innovative work in genetics, particularly regarding the CHD1 gene, has the potential to transform the diagnosis and treatment of coronary heart disease and related metabolic disorders. His contributions to the field are significant and continue to impact medical research and patient care.